BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $774,272 | -17.8% | 20,516 | -0.8% | 0.19% | -14.2% |
| Q2 2023 | $941,906 | +0.2% | 20,674 | -10.8% | 0.23% | -4.2% |
| Q1 2023 | $940,058 | +79096.1% | 23,177 | -0.4% | 0.24% | -20.3% |
| Q4 2022 | $1,187 | -99.9% | 23,279 | +36.5% | 0.30% | +24.4% |
| Q3 2022 | $918,000 | +176.5% | 17,053 | +230.0% | 0.24% | +183.3% |
| Q2 2022 | $332,000 | -21.3% | 5,167 | -5.1% | 0.08% | -7.7% |
| Q1 2022 | $422,000 | -18.4% | 5,445 | -9.6% | 0.09% | -11.7% |
| Q4 2021 | $517,000 | +15.7% | 6,020 | +8.5% | 0.10% | +5.1% |
| Q3 2021 | $447,000 | +21.1% | 5,548 | +21.3% | 0.10% | +12.6% |
| Q2 2021 | $369,000 | -0.3% | 4,575 | +4.1% | 0.09% | -31.5% |
| Q1 2021 | $370,000 | -2.1% | 4,395 | -6.6% | 0.13% | -2.3% |
| Q4 2020 | $378,000 | +1.1% | 4,706 | +1.2% | 0.13% | -16.7% |
| Q3 2020 | $374,000 | -9.9% | 4,649 | -3.5% | 0.16% | -15.2% |
| Q2 2020 | $415,000 | +5.1% | 4,817 | -1.0% | 0.18% | -8.0% |
| Q1 2020 | $395,000 | -3.9% | 4,867 | -1.2% | 0.20% | +19.8% |
| Q4 2019 | $411,000 | -4.4% | 4,924 | 0.0% | 0.17% | -7.7% |
| Q3 2019 | $430,000 | +8.6% | 4,924 | +2.0% | 0.18% | +7.1% |
| Q2 2019 | $396,000 | -1.2% | 4,827 | -2.0% | 0.17% | -2.3% |
| Q1 2019 | $401,000 | +23.8% | 4,927 | 0.0% | 0.17% | +12.3% |
| Q4 2018 | $324,000 | -16.3% | 4,927 | -1.8% | 0.15% | 0.0% |
| Q3 2018 | $387,000 | +4.6% | 5,016 | 0.0% | 0.15% | -1.9% |
| Q2 2018 | $370,000 | +13.5% | 5,016 | 0.0% | 0.16% | +12.9% |
| Q1 2018 | $326,000 | +0.9% | 5,016 | +0.1% | 0.14% | +7.8% |
| Q4 2017 | $323,000 | +2.5% | 5,009 | 0.0% | 0.13% | -3.0% |
| Q3 2017 | $315,000 | +4.0% | 5,009 | 0.0% | 0.13% | -1.5% |
| Q2 2017 | $303,000 | +12.2% | 5,009 | -3.8% | 0.14% | +13.4% |
| Q1 2017 | $270,000 | +24.4% | 5,209 | +6.3% | 0.12% | +26.6% |
| Q4 2016 | $217,000 | -3.1% | 4,900 | +4.3% | 0.09% | -4.1% |
| Q3 2016 | $224,000 | +5.7% | 4,700 | 0.0% | 0.10% | +12.6% |
| Q2 2016 | $212,000 | +5.5% | 4,700 | -4.1% | 0.09% | +4.8% |
| Q1 2016 | $201,000 | -25.8% | 4,900 | -31.0% | 0.08% | -21.0% |
| Q4 2015 | $271,000 | +8.4% | 7,097 | -6.8% | 0.10% | +9.4% |
| Q3 2015 | $250,000 | -65.2% | 7,615 | -25.9% | 0.10% | -62.1% |
| Q2 2015 | $719,000 | -3.0% | 10,280 | -5.0% | 0.25% | -0.4% |
| Q1 2015 | $741,000 | – | 10,821 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |